In this year in review, two infectious diseases pharmacists identify some of the top infectious diseases articles of 2019.
Written By: Bassam Ghanem, Pharm.D., MS, BCPS
Edited By: Timothy P. Gauthier, Pharm.D., BCPS-AQ ID
[Last updated 17 December 2019]
In 2019 we published a monthly column that identified some of the newest journal articles in the field of infectious diseases and antimicrobial stewardship. The goal of the column was to leverage content circulating on Twitter and put it all in one place to help people stay current. Now that 2019 is coming to a close, we thought it might be a good time to reflect on all of the amazing things that came out this year.
We should note that absence from this list does not necessarily indicate reduced importance and this list was composed out of general curiosity, rather than as an academic endeavor resulting from strict selection methodology. We will note that original research articles are the focus of this list.
In case you missed it, here are some of our favorite articles that came out in 2019.
Randomized Controlled Trials
1. Oral versus intravenous antibiotics for bone and joint infection | NEJM
2. Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial | Ann Rheum Dis
3. Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomised, double-blind, placebo-controlled, non-inferiority trial | CMI
4. Antibiotic treatment versus no treatment for asymptomatic bacteriuria in kidney transplant recipients: a multicenter randomized trial | OFID
5. Oral vs Intravenous Antibiotics for Patients With Klebsiella pneumoniae Liver Abscess: A Randomized, Controlled Noninferiority Study | CID
6. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia | AAC
7. Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial | Lancet
8. Four versus six weeks of antibiotic therapy for osteoarticular infections after implant removal: a randomized trial | JAC
9. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure | CID
10. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial | Lancet
11. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis | NEJM
Systematic Reviews & Meta-analysis
1. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteremia: a systematic review and meta-analysis | CMI
2. Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. Beta-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis | OFID
3. Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis | OFID
Prospective & Retrospective Interventional Studies
1. Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes | CID
2. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort | AIM
3. Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study | Lancet Infect Dis
4. Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events | JAMA Surgery
5. Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study | Annals of Internal Medicine
6. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa | CID
7. Use of oral vancomycin for Clostridioides difficile Infection (CDI) and the risk of vancomycin-resistant Enterococci (VRE) | CID
We hope you have found this article helpful. Please share it with your colleagues on social media if they might also find it helpful!
Disclosures: The views and opinions expressed in this article are those of the authors and do not necessarily reflect the policy or opinions of any previous, current, or potential future employer.
RECOMMENDED TO YOU